We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck and Lundbeck Halt Phase III Insomnia Drug Trial
Merck and Lundbeck Halt Phase III Insomnia Drug Trial
March 28, 2007
Merck and Lundbeck announced they are stopping their entire development program for gaboxadol, an investigational new insomnia drug, in the midst of a Phase III clinical trial.